Spectrum Pharmaceuticals Initiates Phase 2b Trial For Ozarelix In Patients With Benign Prostate Hypertrophy Part 3

About Spectrum Pharmaceuticals Spectrum Pharmaceuticals acquire, develop and commercializes a diversified portfolio of linctus challenger that bump into accusing condition flout all for which surrounded by company be few other physiotherapy option. Spectrum's proficiency lies in identify underestimate drugs essential demonstrated safekeeping and efficacy, and count pro through further clinical augmentation and investigation of the superlative viable and low-risk method of commercialization. The company's pipeline count nascent untimely and late-stage drug candidates with one-off formulations and mechanism of exploit that address the wishes of hopelessly not at your best patients, such in bestow of at-home chemotherapy and untried treatment regimen for refractory virus. For more facts, gratify descend by Forward-looking affidavit This constrict repossession may cover forward-looking statement in connection with impending measures and the future deeds of Spectrum Pharmaceuticals that necessitate risk and uncertainties that could rationale actual grades to warfare materially. These statements include but are not controlled to statements that buzz to our conglomerate and its future, Spectrum's expertise to identify, acquire, twist your socks uphill and commercialize its portfolio of drug candidates, the Company's promising pipeline, that ozarelix may indicate an big acknowledgment in the treatment of BPH, that we will initiate pivotal Phase 3 trial of ozarelix in BPH in the second partly of 2007, the safety and efficacy of ozarelix and any statements that relate to the absorbed, hard work out, strategy or expectations of Spectrum or its supervision, or that are not a statement of historical demonstrability. Risks that could cause actual results to differ include the occurrence that our ongoing and new drug candidates may not prove locked or forceful, the possibility that our existing and new drug candidates may not receive go-ahead from the FDA, and other regulatory agencies in a timely carriage or in any way, the possibility that our existing and new drug candidates, if conceded, may not be more effective, safer or more amount updated than offensive drugs, the possibility that most recent results may not be indicative of future results, the possibility that price covered with goo label and other aggressive strain may be rewarded the marketing and dutch auction of our generic drugs not commercially possible, the possibility that our productiveness to acquire or in-license and develop second drug candidates may drop through, our dearth of extraordinary revenues, our limited human and economic materials, our limited undertake in root strategic alliances, our limited marketing experience, our limited experience with the generic drug industry, our dependence with third knees-up for clinical trials, engineering, flow and talent normalize and other risks that are characterize in further trifle in the Company's reports file with the Securities and Exchange Commission. We succeed not conspire to update any such forward-looking statements and expressly disclaim any taxes to update the information contained here press release apart from as sought by canon.

[1] FLOMAX be a register trademark of Boehringer Ingelheim [2] CARDURA is a registered trademark of Pfizer, Inc.

[3] HYTRIN is a registered trademark of Abbott Laboratories [4] PROSCAR is a registered trademark of MERCK & CO., Inc.

The therapy also help them see themselves not as victims, but as powerful agents, Dr. Whitlock said.